Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metreleptin in familial partial lipodystrophy over 12 months
NL-OMON59994Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of metreleptin in familial partial lipodystrophy (FPLD) (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Change from baseline to Month 6 in glycated hemoglobin and Percent change from baseline to Month 6 in fasting triglycerides. Started Mar 2024; status: completed.
02
Drugs
metreleptin
03
Conditions
familial partial lipodystrophy (FPLD)
Beyond the preview
Go deeper on NL-OMON59994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59994.